论文部分内容阅读
18例脓毒症患者随机分为两组,对照组进行常规抗感染、液体复苏、控制血糖、基础病因治疗等,治疗组在常规治疗基础上加低分子肝素钙0.6 ml皮下注射,1次/12 h,疗程7 d。发现治疗组治疗后APACHEⅡ评分较治疗前及对照组治疗后明显下降;治疗组住ICU时间和28 d病死率低于对照组,但无统计学差异;两组治疗前后各凝血指标均无明显改变。认为低分子肝素用于脓毒症患者临床应用安全,是一种有前景的治疗手段。
18 patients with sepsis were randomly divided into two groups, the control group were routinely anti-infective, fluid resuscitation, blood glucose control, the underlying cause of treatment, the treatment group on the basis of conventional treatment plus subcutaneous injection of low molecular weight heparin 0.6 ml, 1 / 12 h, treatment 7 d. The APACHEⅡscore of the treatment group was significantly lower than that of the control group before and after treatment. The ICU time and the 28-day mortality of the treatment group were lower than those of the control group, but there was no significant difference. The coagulation indexes of the two groups had no significant changes . The low molecular weight heparin is considered as a promising treatment for the clinical use of sepsis patients.